Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab + Avonex in RRMS (SENTINEL)
NCT00030966Phase 3Completed
- Sponsor
- Biogen
- Start
- Jan 2002
- Primary completion
- Apr 2005
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Jan 2002; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00030966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030966.